GNFTF - Genfit And GenKyoTex: The Clinical Promise In PBC
Nothing can dim the light that shines from within - Maya Angelou
Introduction
Genfit (GNFTF) and GenKyoTex (GKTX.PA) are both French clinical-stage biopharmaceutical companies with unique and different therapeutic approaches to primary biliary cholangitis ((PBC)). I previously affirmed the potential clinical promise of these drug candidates as second-line therapies in PBC. Both recently provided clinical data to demonstrate the therapeutic merit of their respective drug candidates, which is the focus of this article.
My Insights On Genfit
Genfit, a small market cap ($705M) biopharma, focuses on the early diagnosis and preventive treatment